Sotera Health initiated with an Outperform at BMO Capital

BMO Capital analyst Sean Dodge initiated coverage of Sotera Health (SHC) with an Outperform rating and $19 price target The macro and industry headwinds that have dragged on Solera’s growth over the last 2-3 years have finally begun to dissipate, which paves the way for a re-acceleration in both revenue and EBITDA growth back toward management’s longer-range 5%-7% and 5%-8% targets, the analyst tells investors in a research note. Ongoing litigation remains a risk, but is already discounted into the current valuation.